Day Lucy, CFO of AN2 Therapeutics, Inc. (ANTX), made two open market sales of common shares in the last year, totaling $8,883. Her most recent sale occurred on January 6, 2026. These transactions rank 11,296th out of 11,678 insiders in the database, well below the average sale amount of $8.6 million across 6.4 transactions per insider. Lucy had no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | D | Stock Option (right to buy) | 82300 | $0.00 | 0.0000 | 30,276,230 | 100.00% | 0.27% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | D | Stock Option (right to buy) | 73665 | $0.00 | 0.0000 | 30,276,230 | 100.00% | 0.24% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | A | Stock Option (right to buy) | 66000 | $0.00 | 66,000.0000 | 30,276,230 | 9999.99% | 0.22% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | D | Stock Option (right to buy) | 66000 | $0.00 | 0.0000 | 30,276,230 | 100.00% | 0.22% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | A | Stock Option (right to buy) | 82300 | $0.00 | 82,300.0000 | 30,276,230 | 9999.99% | 0.27% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | A | Stock Option (right to buy) | 73665 | $0.00 | 73,665.0000 | 30,276,230 | 9999.99% | 0.24% |
| Feb. 20, 2026 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | A | Stock Option (right to buy) | 77000 | $0.00 | 77,000.0000 | 30,276,230 | 50.00% | 0.25% |
| Feb. 20, 2026 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | A | Common Stock | 38000 | $0.00 | 118,363.0000 | 30,276,230 | 47.29% | 0.13% |
| Jan. 5, 2026 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | S | Common Stock | 3295 | $1.00 | 80,875.0000 | 30,276,230 | 3.91% | 0.01% |
| Jan. 6, 2026 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | S | Common Stock | 5512 | $1.01 | 75,363.0000 | 30,276,230 | 6.82% | 0.02% |
| Feb. 26, 2025 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | A | Common Stock | 46500 | $0.00 | 79,170.0000 | 29,828,227 | 142.33% | 0.16% |
| Feb. 26, 2025 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | A | Stock Option (right to buy) | 93000 | $0.00 | 93,000.0000 | 29,828,227 | 50.00% | 0.31% |
| Jan. 3, 2025 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | S | Common Stock | 2957 | $1.34 | 32,670.0000 | 29,828,227 | 8.30% | 0.01% |
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | A | Common Stock | 27500 | $0.00 | 30,627.0000 | 23,600,107 | 879.44% | 0.12% |
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | A | Common Stock | 27500 | $0.00 | 30,627.0000 | 23,600,107 | 879.44% | 0.12% |
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | A | Stock Option (right to buy) | 55000 | $0.00 | 55,000.0000 | 23,600,107 | 9999.99% | 0.23% |
| Feb. 15, 2023 | AN2 Therapeutics, Inc. | $ANTX | Day Lucy | Chief Financial Officer | A | Stock Option (right to buy) | 82300 | $0.00 | 82,300.0000 | 0 | 9999.99% | 0.00% |